Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025

Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek ...
Samaa TV

Survival in aggressive breast cancer boosts with THESE treatments

AstraZeneca and Daiichi Sankyo’s Datroway boosts survival in triple-negative breast cancer, showing strong results at ESMO ...
STAT

At ESMO, AstraZeneca, Gilead square off in triple-negative breast cancer

AstraZeneca and Gilead both reported successful trials in a hard-to-treat form of breast cancer, sparking a debate about ...

Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 ...

Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in ...
Fierce Pharma

ESMO: AZ, Daiichi's Datroway outshines Gilead's Trodelvy in first global TROP2 showdown

In the first opportunity for industry watchers to compare the two approved TROP2 antibody-drug conjugates side by side in ...

Gilead's Trodelvy cuts breast cancer risk by 38% in trial

Gilead Sciences' Trodelvy lowered the risk of disease progression in an aggressive type of breast cancer by 38% when used as ...

Gilead Sciences Breaks Out To Record Highs, The Rally Has Room To Run

Discover why Gilead Sciences (GILD) is a top healthcare stock in 2025 with strong fundamentals and growth potential.
MyChesCo on MSN

Unite for HER and TOUCHBBCA Expand Care for Black Breast Cancer Patients With 2025 Program

Unite for HER and TOUCH, The Black Breast Cancer Alliance (TOUCHBBCA), have announced the 2025 Care for HER program, an ...